The effects of a new anti-hypertensive agent (endralazin) upon the general and coronary haemodynamics of the anaesthetized dog.
The effects of a new anti-hypertensive drug (endralazin) was studied in the intact anesthetized dog; in a dose of 150 millimicron/kg intravenously, the drug increased heart rate, respiratory rate, cardiac output and coronary sinus flow. Systemic blood pressure fell 60 min after the injection. The drug decreased calculated peripheral, pulmonary, and coronary vascular resistance,, amd maintained calculated cardiac efficiency. It also increased blood glucose, non-esterified fatty acid, lactate and pyruvate values, but did not influence cardiac usage of these substrates. There was evidence also of catecholamine release during the period of the study.
D000758:Anesthesia; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002395:Catecholamines / Q000378:metabolism; D003326:Coronary Circulation / Q000187:drug effects*; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects*; D010101:Oxygen Consumption / Q000187:drug effects; D011724:Pyridazines / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects
D000959:Antihypertensive Agents; D002395:Catecholamines; D011724:Pyridazines; C014926:BQ 22-708